Who's who in Krka

Jože Colarič (born 1955 in Brežice) finished secondary education at Gimnazija Novo mesto, then continued studies at the Faculty of Economics in Ljubljana and took his degree in 1979.

He has been employed at Krka since 1982. He started work in the Finance Sector, where he initially headed Foreign Currency Payments, and then advanced to Assistant Director. In 1989, he started managing the Exports Department within the Import-Export Sector, and two years later became Deputy Director of Import-Export.

Early in 1993, Colarič was appointed Deputy Chief Executive for Marketing and Finance, and in September of the same year, he also accepted management of Marketing-and-Sales Sector.

In 1997, he was appointed a member to the Management Board. In the following year, the Supervisory Board appointed him Deputy President of the Management Board, and in 2002, acknowledged him as a future president of the Management Board, making him responsible for proposing candidates for the new Management Board team.

At their meeting of 12 July 2004, the Supervisory Board appointed Colarič President of the Management Board and Chief Executive Officer. His five-year term of office began on 1 January 2005. At their meeting of 21 January 2009, the Supervisory Board appointed him for another six-year term of office commencing on 1 January 2010. Under his management, Krka has developed into one of the leading generic pharmaceutical companies in the world and built solid foundations for growth. Colarič’s actions focus on Krka's in-house knowledge, new product development, annual investments, recruitment, and regular dividend payments. In 2015, the Supervisory Board therefore unanimously appointed him President of the Management Board and CEO for a new six-year term of office commencing on 1 January 2016. When that term of office ended, the Supervisory Board appointed him President of the Management Board and CEO for another six-year term of office commencing on 1 January 2022. He put forward the unchanged Management Board, and the Supervisory Board unanimously reappointed the body for the 2022–2027 term of office as proposed.